OptiBiotix operates in the human microbiome market and we see the company at an interesting strategic inflection point, with developing revenues generated from its lead products and showing commercial traction with the next generation of products. We expect the company to generate value from both sets of products and see additional upside from its holding in SkinBioTherapeutics. With increasing interest being shown in targeting the human microbiome to improve health, OptiBiotix is well positione
Companies: OptiBiotix Health PLC
OptiBiotix ("OPTI") recently announced a number of new commercial agreements for marketed functional food ingredients SlimBiome and LP-LDL. These new agreements take the number of commercial deals for both products to 57 and include a mixture of new distribution and manufacturing agreements, not only increasing the number of countries where products containing OPTI's ingredients are sold to over 70, but are also anticipated to improve profitability through the renegotiation of manufacture deals
OptiBiotix ("OPTI") has had a strong start to 2020, with partners Agropur (US), Holland & Barrett (UK) and most recently Alfasigma (Italy) launching new products containing the company's microbiome-modulating functional ingredients. As an increasing number of products move to market, we remain positive as to the commercial potential of OPTI's functional ingredients as consumer awareness grows. The recent launches indicate growing momentum into 2020, when we expect existing agreements to start de
OptiBiotix ("OPTI") has announced that Holland & Barrett, a global nutritional food and supplement retailer, has launched a new product range under the SlimBiome brand. The weight management products, which contain OPTI's proprietary weight management formulation, will initially be available on the Holland & Barrett website and physical stores in the United Kingdom, Republic of Ireland, Netherlands, Belgium and Sweden. The deal marks the 22nd commercial partnership for SlimBiome and the first wi
Research Tree provides access to ongoing research coverage, media content and regulatory news on OptiBiotix Health PLC. We currently have 95 research reports from 5 professional analysts.
Synairgen reported FY 2020 results that showed an adjusted net loss of £13.7m, with year-end cash of £75.0m, some £27m higher than our expectations. The delta can largely be accounted for by delays in starting enrolment into the Phase III trial as well as the treatment of prepayments for drug substance and nebulisers: the latter reflected in working capital rather than expensed through the income statement. Near-term focus remains on the outcome of the Phase III study (SG018), and with the enrol
Companies: Synairgen plc
ANGLE is progressing its proprietary Parsortix cancer diagnostic platform through several key inflection points over the next 24 months, most notably FDA approval. In parallel, it has initiated commercialisation through the creation of two clinical laboratories (in the UK and US), which can offer services to the pharma industry and LDTs (Laboratory Developed Tests) for the clinical market. Parsortix is an elegant microfluidic device that captures circulating tumour cells (CTCs) for analysis. Suc
Companies: ANGLE plc
Medica reported FY2020 results this morning which given the prelim update in January were largely as expected. A resilient performance in the NightHawk business (+4%) offset COVID driven weakness in the Elective Business (-49%) meaning group revenue of £36.8m was as expected. EPS of 3.47p was also largely as anticipated. More importantly, the business appears to be tracking in-line with our 2021 forecasts as the Elective recovery gathers pace and hence we don’t expect any changes to estimates. O
Companies: Medica Group Plc
The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa
Companies: AMYT ARBB BPC BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN
RUA Life Sciences has provided a trading statement for the year ending March 2021. Through the year the group achieved its objectives including the integration of RUA Medical, lead product development ahead of expected submission in June 21 and proof of concept accomplished on the polymeric heart valve. Revenues for the year are expected to be in line with our forecast of £1.4m and the group closed the year with cash of £6.4m, ahead of our £5.2m expectation. We believe RUA Life Sciences is in a
Companies: RUA Life Sciences Plc
The market is overly focussed on the 2021 recovery which we believe is on-track to meet our 6% ahead of consensus forecasts. This focus means the uniqueness of the longer-term story is being overlooked. Medica is set to deliver the fastest and most visible revenue growth in the sector (14% CAGR to 2025) whilst the pricing/margin backdrop is also improving allowing this to drop through to a 22% EPS CAGR. This overlooked story means the shares trade on a 30% peer discount. Medica remains our Top P
Futura received full EU approval for MED3000 this morning following indicative approval last month. This removes the last hurdle to signing meaningful commercial agreements in our view. We have reassessed our sales forecasts to account for its over-the-counter rather than prescription status which drives longer-term upgrades. This more valuable commercial proposition helps to drive an upgrade of our TP to £0.80 (c.80% upside) from £0.68. We expect the start of the US study, regulatory approvals
Companies: Futura Medical plc
MAST Energy Developments (MED) is to IPO on the Standard List on 14th April 2021 under the ticker MAST. The company has raised £5m giving a market capitalisation on listing of c. £23m. MED is currently a 100% subsidiary company of AIM quoted, Kibo Energy*. MED was established to acquire and develop a portfolio of flexible power plants in the UK and become a multi-asset operator in the rapidly growing Reserve Power market. PensionBee has confirmed its intention to float on the High Growth Se
Companies: SYM CGNR EKF KBT GGP VLS TMO ECK B90 MDZ
Ahead of its FY 2021 results in July, RUA Life Sciences’ trading update included its first year after the acquisition of RUA Medical and a period where the pandemic brought challenges to its customers. While FY 2021 marked a period of transformation for RUA Life Sciences and the medical device market, some things stayed the same as the progress in RUA’s products in RUA Vascular and RUA Structural Heart have continued unabated despite the pandemic.
…leads us to substantially upgrade our forecasts
Companies: SDI Group plc
Circassia is now focussed on NIOX, a gold standard device for diagnosing and managing asthma patients. It is the global market leader in FeNO testing and has regulatory approval and agreed reimbursement in all major territories. A new management team has rapidly addressed legacy issues, eliminating a substantial debt overhang, rightsizing the cost base and optimising routes to market. Whilst the Covid-19 pandemic has impacted revenues, we see scope for a rapid recovery as activity normalises. Th
Companies: Circassia Group PLC
In what has been a very challenging year with numerous headwinds, FY20 results are slightly ahead of recently upgraded estimates and clearly underline the benefits of operating leverage as VLG brands and volume throughput in Italy scale up. The 500bps uplift in the EBITDA margin to 19% included headwinds worth almost 300bps relating to covid costs and debtor provision (China) – both of which should not feature in the future. There is no news on M&A at this stage, but investors will be encouraged
Companies: Venture Life Group Plc
Having upgraded several times in the year, EKF’s FY20 results are as expected and show a step change in the performance of the business. Whilst this has been catalysed by the pandemic and sales of sample collection devices, the core business has held up relatively well and is showing an encouraging return to growth in Q1. The main new news this morning is a significant multi-year, multi-million dollar contract expansion for sample collection devices with a multinational private sector partner. W
Companies: EKF Diagnostics Holdings plc
Semper Fortis Esports* recently announced its intention to IPO onto the Access Segment of the Aquis Stock Exchange Growth Market. Semper is a multi-operational Esports organisation focusing on gaming technology solutions, brand enhancement and high growth team infrastructures. The company plans to raise £2.5m to develop their three core areas of establishing an esports team, forming partnerships with brands for sponsorship and B2B consultancy services. The Board are highly experienced in spor
Companies: KIBO ROCK VRCI K3C TOU ADT PCA ATYM IOM MJH
Semper Fortis Esports* recently announced its intention to IPO onto the Access Segment of the Aquis Stock Exchange Growth Market. Semper is a multi-operational Esports organisation focusing on gaming technology solutions, brand enhancement and high growth team infrastructures. The company plans to raise £2.5m to develop their three core areas of establishing an esports team, forming partnerships with brands for sponsorship and B2B consultancy services. The Board are highly experienced in sports
Companies: KIBO MTW GWI MTR DUKE ITM GDR MSMN CMCL PTRO
